Article ID Journal Published Year Pages File Type
5887757 Seminars in Arthritis and Rheumatism 2014 11 Pages PDF
Abstract
Response rates were comparable among anti-TNF agents. Overall, 5-year drug survival was below 50%, with infliximab demonstrating increased safety-related discontinuations. Remission rates are low in clinical practice. Strategies to increase effectiveness and long-term survival of anti-TNF agents in RA are needed.
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Authors
, , , , , , , , , , , , , , ,